Rosuvastatin therapy , as compared with placebo , was associated with fewer days free of renal failure to day 14 ( 10.15.3 vs. 11.04.7 , P = 0.01 ) and fewer days free of hepatic failure to day 14 ( 10.85.0 vs. 11.84.3 , P = 0.003 ) .